Literature DB >> 19605524

Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways.

Rithwik Ramachandran1, Koichiro Mihara, Maneesh Mathur, Moulay Driss Rochdi, Michel Bouvier, Kathryn Defea, Morley D Hollenberg.   

Abstract

We evaluated the ability of different trypsin-revealed tethered ligand (TL) sequences of rat proteinase-activated receptor 2 (rPAR(2)) and the corresponding soluble TL-derived agonist peptides to trigger agonist-biased signaling. To do so, we mutated the proteolytically revealed TL sequence of rPAR(2) and examined the impact on stimulating intracellular calcium transients and mitogen-activated protein (MAP) kinase. The TL receptor mutants, rPAR(2)-Leu(37)Ser(38), rPAR(2)-Ala(37-38), and rPAR(2)-Ala(39-42) were compared with the trypsin-revealed wild-type rPAR(2) TL sequence, S(37)LIGRL(42)-. Upon trypsin activation, all constructs stimulated MAP kinase signaling, but only the wt-rPAR(2) and rPAR(2)-Ala(39-42) triggered calcium signaling. Furthermore, the TL-derived synthetic peptide SLAAAA-NH2 failed to cause PAR(2)-mediated calcium signaling but did activate MAP kinase, whereas SLIGRL-NH2 triggered both calcium and MAP kinase signaling by all receptors. The peptides AAIGRL-NH2 and LSIGRL-NH2 triggered neither calcium nor MAP kinase signals. Neither rPAR(2)-Ala(37-38) nor rPAR(2)-Leu(37)Ser(38) constructs recruited beta-arrestins-1 or -2 in response to trypsin stimulation, whereas both beta-arrestins were recruited to these mutants by SLIGRL-NH2. The lack of trypsin-triggered beta-arrestin interactions correlated with impaired trypsin-activated TL-mutant receptor internalization. Trypsin-stimulated MAP kinase activation by the TL-mutated receptors was not blocked by inhibitors of Galpha(i) (pertussis toxin), Galpha(q) [N-cyclohexyl-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno[1,2-c]pyrazole-3-carboxamide (GP2A)], Src kinase [4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1)], or the epidermal growth factor (EGF) receptor [4-(3'-chloroanilino)-6,7-dimethoxy-quinazoline (AG1478)], but was inhibited by the Rho-kinase inhibitor (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 2HCl (Y27362). The data indicate that the proteolytically revealed TL sequence(s) and the mode of its presentation to the receptor (tethered versus soluble) can confer biased signaling by PAR(2), its arrestin recruitment, and its internalization. Thus, PAR(2) can signal to multiple pathways that are differentially triggered by distinct proteinase-revealed TLs or by synthetic signal-selective activating peptides.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605524      PMCID: PMC2769049          DOI: 10.1124/mol.109.055509

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

1.  Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands.

Authors:  A Kawabata; M Saifeddine; B Al-Ani; L Leblond; M D Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

2.  Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function.

Authors:  V Vouret-Craviari; P Boquet; J Pouysségur; E Van Obberghen-Schilling
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

3.  Molecular cloning of a potential proteinase activated receptor.

Authors:  S Nystedt; K Emilsson; C Wahlestedt; J Sundelin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

4.  Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration.

Authors:  T M Seasholtz; M Majumdar; D D Kaplan; J H Brown
Journal:  Circ Res       Date:  1999-05-28       Impact factor: 17.367

5.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.

Authors:  M Uehata; T Ishizaki; H Satoh; T Ono; T Kawahara; T Morishita; H Tamakawa; K Yamagami; J Inui; M Maekawa; S Narumiya
Journal:  Nature       Date:  1997-10-30       Impact factor: 49.962

6.  Proteinase-activated receptor-2: key role of amino-terminal dipeptide residues of the tethered ligand for receptor activation.

Authors:  Bahjat Al-Ani; Kristina K Hansen; Morley D Hollenberg
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

7.  Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation.

Authors:  J H Hanke; J P Gardner; R L Dow; P S Changelian; W H Brissette; E J Weringer; B A Pollok; P A Connelly
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

8.  Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation.

Authors:  Dalila Darmoul; Valérie Gratio; Hélène Devaud; Marc Laburthe
Journal:  J Biol Chem       Date:  2004-03-09       Impact factor: 5.157

9.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors.

Authors:  H Daub; F U Weiss; C Wallasch; A Ullrich
Journal:  Nature       Date:  1996-02-08       Impact factor: 49.962

10.  Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2.

Authors:  S K Bohm; W Kong; D Bromme; S P Smeekens; D C Anderson; A Connolly; M Kahn; N A Nelken; S R Coughlin; D G Payan; N W Bunnett
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

View more
  49 in total

Review 1.  Signal transduction by protease-activated receptors.

Authors:  Unice J K Soh; Michael R Dores; Buxin Chen; JoAnn Trejo
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

2.  Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury.

Authors:  Silvio Antoniak; Mauricio Rojas; Denise Spring; Tara A Bullard; Edward D Verrier; Burns C Blaxall; Nigel Mackman; Rafal Pawlinski
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-19       Impact factor: 8.311

Review 3.  Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.

Authors:  M D Hollenberg; K Mihara; D Polley; J Y Suen; A Han; D P Fairlie; R Ramachandran
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 4.  Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection.

Authors:  M D Hollenberg
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

5.  Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis.

Authors:  Justin Hoffman; Andrea N Flynn; Dipti V Tillu; Zhenyu Zhang; Renata Patek; Theodore J Price; Josef Vagner; Scott Boitano
Journal:  Bioconjug Chem       Date:  2012-10-08       Impact factor: 4.774

Review 6.  Roles of proteolysis in regulation of GPCR function.

Authors:  G S Cottrell
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Collagenolytic matrix metalloproteinases antagonize proteinase-activated receptor-2 activation, providing insights into extracellular matrix turnover.

Authors:  Adrian M D Falconer; Chun Ming Chan; Joseph Gray; Izuru Nagashima; Robert A Holland; Hiroki Shimizu; Andrew R Pickford; Andrew D Rowan; David J Wilkinson
Journal:  J Biol Chem       Date:  2019-05-19       Impact factor: 5.157

8.  The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.

Authors:  M S Grace; T Lieu; B Darby; F C Abogadie; N Veldhuis; N W Bunnett; P McIntyre
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

9.  Polarization of protease-activated receptor 2 (PAR-2) signaling is altered during airway epithelial remodeling and deciliation.

Authors:  Ryan M Carey; Jenna R Freund; Benjamin M Hariri; Nithin D Adappa; James N Palmer; Robert J Lee
Journal:  J Biol Chem       Date:  2020-04-02       Impact factor: 5.157

10.  Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.

Authors:  Valérie Gratio; Nathalie Beaufort; Lina Seiz; Josefine Maier; G Duke Virca; Mekdes Debela; Nicolai Grebenchtchikov; Viktor Magdolen; Dalila Darmoul
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.